New combo therapy aims to shrink head and neck tumors before surgery
NCT ID NCT05758389
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This phase 2 trial tests whether adding the immunotherapy drug tislelizumab to chemotherapy before surgery or chemoradiation helps people with advanced head and neck cancer. About 29 participants will receive the combination, and doctors will check if tumors shrink or disappear. The study also looks at side effects and genetic markers that might predict response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Oncology, Drum Tower Hospital, Nanjing University School of Medicine
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (PD-1 inhibitor) combined with paclitaxel, cisplatin, and 5-FU
What this could lead to
If successful, this could offer a new treatment option that shrinks tumors before surgery or chemoradiation, potentially improving outcomes for people with advanced head and neck cancer.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. The combination therapy can cause significant side effects, and it's too soon to know if it works better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.